Viatris Valuation
Is VTRS * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VTRS * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VTRS * (MX$250) is trading below our estimate of fair value (MX$914.63)
Significantly Below Fair Value: VTRS * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VTRS *?
Key metric: As VTRS * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is VTRS *'s PS Ratio? | |
|---|---|
| PS Ratio | 1x |
| Sales | US$15.05b |
| Market Cap | US$15.61b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | 6.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does VTRS *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.8x | ||
LAB B Genomma Lab Internacional. de | 1.4x | 9.9% | Mex$24.0b |
RPRX Royalty Pharma | 5.2x | 7.2% | US$11.8b |
000538 Yunnan Baiyao GroupLtd | 2.6x | 6.4% | CN¥100.8b |
SDZ Sandoz Group | 2x | 5.7% | CHF 17.7b |
VTRS * Viatris | 1x | -1.1% | Mex$15.6b |
Price-To-Sales vs Peers: VTRS * is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (2.8x).
Price to Sales Ratio vs Industry
How does VTRS *'s PS Ratio compare vs other companies in the Global Pharmaceuticals Industry?
| 191 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 191 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: VTRS * is good value based on its Price-To-Sales Ratio (1x) compared to the Global Pharmaceuticals industry average (2.6x).
Price to Sales Ratio vs Fair Ratio
What is VTRS *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate VTRS *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | Mex$266.76 0% | 8.9% | Mex$305.83 | Mex$244.66 | n/a | 8 |
| Nov ’25 | n/a | Mex$242.89 0% | 9.7% | Mex$282.51 | Mex$207.18 | n/a | 8 |
| Oct ’25 | n/a | Mex$242.89 0% | 9.7% | Mex$282.51 | Mex$207.18 | n/a | 8 |
| Sep ’25 | Mex$229.99 | Mex$242.89 +5.6% | 9.7% | Mex$282.51 | Mex$207.18 | n/a | 8 |
| Aug ’25 | n/a | Mex$228.66 0% | 10.3% | Mex$271.22 | Mex$198.90 | n/a | 8 |
| Jul ’25 | n/a | Mex$210.31 0% | 6.9% | Mex$237.52 | Mex$186.62 | n/a | 8 |
| Jun ’25 | n/a | Mex$210.31 0% | 6.9% | Mex$237.52 | Mex$186.62 | n/a | 8 |
| May ’25 | Mex$192.00 | Mex$206.44 +7.5% | 7.0% | Mex$233.17 | Mex$183.20 | n/a | 9 |
| Apr ’25 | Mex$196.05 | Mex$206.07 +5.1% | 7.0% | Mex$232.74 | Mex$182.87 | n/a | 9 |
| Mar ’25 | Mex$218.00 | Mex$204.34 -6.3% | 9.6% | Mex$239.37 | Mex$170.98 | n/a | 9 |
| Feb ’25 | Mex$201.50 | Mex$202.00 +0.2% | 11.1% | Mex$241.12 | Mex$172.23 | n/a | 9 |
| Jan ’25 | n/a | Mex$197.27 0% | 12.7% | Mex$237.72 | Mex$152.82 | n/a | 9 |
| Dec ’24 | n/a | Mex$199.62 0% | 13.5% | Mex$240.67 | Mex$154.71 | n/a | 8 |
| Nov ’24 | Mex$151.00 | Mex$213.20 +41.2% | 13.9% | Mex$254.30 | Mex$163.48 | n/a | 8 |
| Oct ’24 | Mex$159.76 | Mex$220.24 +37.9% | 11.2% | Mex$261.03 | Mex$174.02 | n/a | 9 |
| Sep ’24 | n/a | Mex$212.96 0% | 12.0% | Mex$256.46 | Mex$170.98 | Mex$229.99 | 9 |
| Aug ’24 | Mex$177.00 | Mex$210.60 +19.0% | 12.0% | Mex$255.90 | Mex$170.60 | n/a | 9 |
| Jul ’24 | Mex$172.50 | Mex$216.08 +25.3% | 11.9% | Mex$259.09 | Mex$172.73 | n/a | 10 |
| Jun ’24 | n/a | Mex$227.50 0% | 11.8% | Mex$269.64 | Mex$179.76 | n/a | 9 |
| May ’24 | Mex$165.99 | Mex$227.50 +37.1% | 11.8% | Mex$269.64 | Mex$179.76 | Mex$192.00 | 9 |
| Apr ’24 | Mex$170.00 | Mex$251.38 +47.9% | 17.3% | Mex$338.82 | Mex$188.23 | Mex$196.05 | 11 |
| Mar ’24 | n/a | Mex$244.59 0% | 16.7% | Mex$329.37 | Mex$182.98 | Mex$218.00 | 12 |
| Feb ’24 | Mex$215.00 | Mex$250.45 +16.5% | 16.9% | Mex$335.18 | Mex$186.21 | Mex$201.50 | 12 |
| Jan ’24 | Mex$210.00 | Mex$257.14 +22.4% | 18.2% | Mex$348.72 | Mex$193.73 | n/a | 11 |
| Dec ’23 | n/a | Mex$257.14 0% | 18.2% | Mex$348.72 | Mex$193.73 | n/a | 11 |
| Nov ’23 | n/a | Mex$250.03 0% | 22.4% | Mex$358.74 | Mex$179.37 | Mex$151.00 | 11 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a
Incyte
US$13.8b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally.
INCY *
US$1,486.00
7D
0%
1Y
n/a